365ËÙ·¢¹ú¼Ê

365ËÙ·¢¹ú¼Ê(Öйú)¹Ù·½ÍøÕ¾

ÖÕÓÚ£¡¿ÆÑ§¼Ò·¢Ã÷Á˳£ÓÃÒ»Ïß»¯ÁÆÒ©×Ïɼ´¼Ôö½ø°©Ö¢×ªÒƱ³ºóµÄ»úÖÆ

ʱ¼ä£º2017-09-07     ÈªÔ´£ºÆæµãÍø

×ÔÉϸöÊÀ¼ÍÏÂÒ¶±»·¢Ã÷ÒÔÀ´£¬£¬£¬£¬£¬×Ïɼ´¼£¨Paclitaxel£¬£¬£¬£¬£¬PTX£©¾ÍÒ»Ö±ÊÇ»¯ÁƽçµÄÃ÷ÐÇ¡£¡£¡£¡£ ¡£¡£ÓÉÓÚÆä¸ß¶È¿¹°©»îÐÔ£¬£¬£¬£¬£¬×Ïɼ´¼ÏÖÔÚÒѾ­±»ÆÕ±éÓ¦ÓÃÓÚÂѳ²°©¡¢ÈéÏÙ°©¡¢·Î°©µÈ¶àÖÖ°©Ö¢µÄÒ»ÏßÖÎÁÆ[1]¡£¡£¡£¡£ ¡£¡£Ææµã¸â»¹¼ÇµÃÒ»¾­ÓйýÐÂÎÅ£¬£¬£¬£¬£¬×Ïɼ´¼µÄÖÊÁϺ춹ɼ±»ÀèÃñ°þÁËÊ÷ƤÅݾƣ¬£¬£¬£¬£¬ÒýΪ¿¹°©“ÉñÒ©”£¨ËäÈ»ÁË£¬£¬£¬£¬£¬ÕâÊǸö¹ýʧµÄ×ö·¨£¬£¬£¬£¬£¬Ö±½Ó·þÓú춹ɼ¿ÉÊÇ»áÖж¾µÄ£©¡£¡£¡£¡£ ¡£¡£

²»¹ý£¬£¬£¬£¬£¬×Ïɼ´¼µÄ×÷ÓÃÒ²ÊǰÑË«Èн££¬£¬£¬£¬£¬ÔÚʹÓÃϸ°û¶¾ÐÔɱËÀ°©Ï¸°ûµÄͬʱ£¬£¬£¬£¬£¬ËüÒ²»áÔöÌí°©Ï¸°û¶Ô»¯ÁƼÁµÄ¿¹ÐÔ²¢Ôö½ø°©Ï¸°û×ªÒÆ¡£¡£¡£¡£ ¡£¡£ÔÚ8Ô·ݵġ¶ÃÀ¹ú¹ú¼Ò¿ÆÑ§ÔºÔº¿¯¡·£¨PNAS£©ÉÏ£¬£¬£¬£¬£¬À´×Ô¶íº¥¶íÖÝÁ¢´óѧÉúÎﻯѧÓëÒ©Àíѧ½ÌÊÚTsonwin HaiÍŶӵÄÒ»ÏîÑо¿Îª×Ïɼ´¼Ôö½øÈéÏÙ°©µÄ·Î×ªÒÆ[2]ÌṩÁ˓ʵ´¸”¡£¡£¡£¡£ ¡£¡£

ͼƬ

Tsonwin Hai½ÌÊÚ

Ñо¿Ð§¹ûÕ¹ÏÖÁËÁ½¸öÖ÷ÒªµÄ»úÖÆ£ºÒ»ÊÇ×Ïɼ´¼»á¸Ä±äÔ­·¢Ö×ÁöÖܱßѪ¹ÜµÄ״̬£¬£¬£¬£¬£¬×ÊÖúÈéÏÙ°©Ï¸°û½øÈëѪѭ»·£»£»¶þÊÇËü»¹»áÔÚ·Î×éÖ¯ÖГÐÁÇÚ¸û×÷”£¬£¬£¬£¬£¬Ê¹·Î×é֯΢ÇéÐθüÊʺϰ©Ï¸°ûÉúÑÄ£¬£¬£¬£¬£¬Ôö½ø°©Ï¸°û“Éú¸ù³éÑ¿”¡£¡£¡£¡£ ¡£¡£¶øÕâЩÓк¦Ó°Ï죬£¬£¬£¬£¬¶¼ÒªÍ¨¹ýÒ»¸öÃûΪAtf3µÄ»ùÒòÀ´ÊµÏÖ¡£¡£¡£¡£ ¡£¡£

Atf3ÊÇÒ»ÖÖÓ¦¼¤¿ì·´Ó¦»ùÒò£¬£¬£¬£¬£¬Õý³£ÇéÐÎϱí´ïÁ¿ºÜÊǵͣ¬£¬£¬£¬£¬µ±Êܵ½Íâ½çÐźŴ̼¤£¬£¬£¬£¬£¬¾Í»á¿ìËÙ´ó×Ú±í´ï¡£¡£¡£¡£ ¡£¡£±í´ï²úÆ·Atf3ÂѰ×ÊÇÒ»ÖÖת¼Òò×Ó£¬£¬£¬£¬£¬Äܹ»Ö±½Ó»ò¼ä½Óµ÷¿ØÐí¶à¼ÓÈëÑ×Ö¢·´Ó¦µÄ»ùÒòµÄ±í´ï[3]¡£¡£¡£¡£ ¡£¡£

ÄÇôÊÂʵ¿ÆÑ§¼ÒÊÇÔõô֤ʵ×Ïɼ´¼µÄ“Åѱä”ÐÐΪµÄÄØ £¿£¿£¿£¿£¿

Hai½ÌÊÚºÍËýµÄÍŶÓÔÚСÊóÉíÉϾÙÐÐÁËÊÔÑé¡£¡£¡£¡£ ¡£¡£ËûÃǶÔÄܹ»±¬·¢×Ô¾õ×ªÒÆµÄÈéÏÙ°©Ä£×ÓСÊó×¢ÉäÁËÒ»¶¨Á¿µÄ×Ïɼ´¼¡£¡£¡£¡£ ¡£¡£±ÈÆð±ÈÕÕ×飬£¬£¬£¬£¬×¢ÉäÁË×Ïɼ´¼µÄʵÑé×éСÊóÔ­·¢Ö×ÁöȷʵÓÐËõС£¡£¡£¡£ ¡£¡£¬£¬£¬£¬£¬¿ÉÊÇ×ªÒÆµ½·Î²¿µÄ°©Ï¸°ûÈ´¸ü¶à£¡Ñо¿Õß¶ÔÇóýÁËAtf3»ùÒòµÄСÊóÒ²×öÁËͬÑùµÄʵÑ飬£¬£¬£¬£¬Ð§¹ûÈ´²¢Ã»ÓÐʲô²î±ð¡£¡£¡£¡£ ¡£¡£Õâ×ãÒÔ˵Ã÷×Ïɼ´¼µÄÕâÖÖÔö½ø°©Ö¢×ªÒƵÄ×÷ÓÃÓëAtf3»ùÒòÓйØÁË¡£¡£¡£¡£ ¡£¡£

ͼƬ

ÉÏ£ºÔÚµÚ26Ì죬£¬£¬£¬£¬²»Ê¹ÓÃ×Ïɼ´¼ÖÎÁƺÍʹÓÃ×Ïɼ´¼ÖÎÁÆÒÔ¼°ÇóýAtf3»ùÒòºó²»Ê¹ÓÃ×Ïɼ´¼ÖÎÁƺÍʹÓÃ×Ïɼ´¼ÖÎÁƵÄËÄÖÖСÊó·Î×ªÒÆÖ×ÁöÕ¼×ܷβ¿µÄÃæ»ý

Ï£ºËÄÖÖСÊóµÄ·Î²¿ÇÐÆ¬£¬£¬£¬£¬£¬ÉîÉ«²¿·ÖÎª×ªÒÆÁö

ΪÁ˸ãɨ³ý×Ïɼ´¼ºÍAtf3»ùÒò¾¿¾¹ÊÇÔõôʹ»µµÄ£¬£¬£¬£¬£¬Ñо¿Ö°Ô±¶ÔÕ⼸ÖÖÖ×Áö×éÖ¯¾ÙÐÐÁ˼ì²â£¬£¬£¬£¬£¬·¢Ã÷ÓÃ×Ïɼ´¼ÖÎÁƵÄСÊóÖ×Áö×éÖ¯ÖÐ΢Ѫ¹ÜµÄÃܶÈÌØÊâ¸ß£¬£¬£¬£¬£¬²¢ÇÒһЩÄÜ×ÊÖúÖ×Áö×ªÒÆºÍÐÂѪ¹ÜÌìÉúµÄϸ°û£¨±í´ïTie2»ùÒòµÄµ¥ºË¾ÞÊÉϸ°û£¬£¬£¬£¬£¬TEMs£©Ò²ÔöÌíÁË¡£¡£¡£¡£ ¡£¡£ËûÃÇ»¹·¢Ã÷£¬£¬£¬£¬£¬ºÍѪ¹ÜÌìÉúÓйصÄһЩ»ùÒò±í´ïÁ¿¸ß£¨ÈçAng1£¬£¬£¬£¬£¬Notch1ºÍCxcl1£©£¬£¬£¬£¬£¬ºÍ¿¹Ñª¹ÜÌìÉúÓйصÄһЩ»ùÒò±í´ïÁ¿µÍ£¨ÈçCxcl9¡¢10¡¢11ºÍ14£©¡£¡£¡£¡£ ¡£¡£

ÁíÍ⣬£¬£¬£¬£¬ÉÐÓÐÒ»¸öÓÐÒâ˼µÄÕ÷Ï󣬣¬£¬£¬£¬ÈéÏÙ°©Ï¸°ûÀ©É¢ÐèҪͨ¹ýÈýÖÖϸ°ûµÄÖ±½Ó½Ó´¥——ÄÚÆ¤Ï¸°û¡¢Ñª¹ÜÖÜΧ¾ÞÊÉϸ°ûºÍÔöÇ¿°©Ï¸°ûÀ©É¢ÄÜÁ¦µÄMenaÂѰ×ˮƽ¸ßµÄ°©Ï¸°û¡£¡£¡£¡£ ¡£¡£ÒÑÍùµÄÑо¿·¢Ã÷£¬£¬£¬£¬£¬ÕâÈýÖÖϸ°ûÔÚÄÇÀï½Ó´¥£¬£¬£¬£¬£¬°©Ï¸°û¾ÍÔÚÄÇÀï½øÈëѪ¹Ü£¬£¬£¬£¬£¬ØÊºó£¬£¬£¬£¬£¬Õâ¸ö“λµã”±»ÃüÃûΪÖ×Áö×ªÒÆÎ¢ÇéÐΣ¨tumor microenvironment of metastasis£¬£¬£¬£¬£¬TMEM£©[4]¡£¡£¡£¡£ ¡£¡£

ÒÔÊÇ£¬£¬£¬£¬£¬TMEM¾ÍÏ൱ÓÚÒ»ÉÈÃÅ£¬£¬£¬£¬£¬µ±“Èý°ÑÔ¿³×”¾ÛÆëʱ£¬£¬£¬£¬£¬°©Ï¸°û¾Í¿ÉÒÔ·­¿ªÃÅ£¬£¬£¬£¬£¬½øÈëѪ¹ÜÖÐÁË¡£¡£¡£¡£ ¡£¡£ÔÚÕâ´ÎµÄÑо¿ÖУ¬£¬£¬£¬£¬Ñо¿Ö°Ô±Ò²·¢Ã÷£¬£¬£¬£¬£¬Ê¹ÓÃ×Ïɼ´¼ÖÎÁƵÄСÊóTMEMÃܶÈÏÔ×ÅÉý¸ß£¬£¬£¬£¬£¬ÕâҲ˵Ã÷£¬£¬£¬£¬£¬×Ïɼ´¼Îª°©Ï¸°û¶àÔìÁ˼¸ÉÈÃÅ£¬£¬£¬£¬£¬×ÊÖúÁËËüÏò·Î²¿×ªÒÆ¡£¡£¡£¡£ ¡£¡£ÕâºÍ²»¾Ãǰ½ÒÏþÔÚ¡¶¿ÆÑ§×ª»¯Ò½Ñ§¡·ÉϵÄÁíÒ»ÏîÑо¿“²»Ô¼¶øÍ¬”£¬£¬£¬£¬£¬ËûÃÇÔÚ»¯ÁƵݩ֢»¼ÕßÉíÉÏÒ²·¢Ã÷ÁËÕâ¸öÕ÷Ïó[5]¡£¡£¡£¡£ ¡£¡£

ÒÔÊÇÕ⼸ÏîÖ¸±êµÄת±äÒâζ×Å£¬£¬£¬£¬£¬×Ïɼ´¼²»µ«¸ø°©Ï¸°û¿ªÍØÁ˸ü¶àµÄ“³ö×ßõè¾¶£¨Î¢Ñª¹Ü£©”£¬£¬£¬£¬£¬»¹°ïËüÃÇ·­¿ªÁËÍÑÀëèäèôµÄ“´óÃÅ£¨TMEM£©”¡£¡£¡£¡£ ¡£¡£

ÒÔÉÏÕâЩЧ¹û¶¼Ö»·ºÆðÔÚÒ°ÉúÐÍСÊóÉÏ£¬£¬£¬£¬£¬ÇóýÁËAtf3»ùÒòµÄСÊóʵÑé×éºÍ±ÈÕÕ×éûÓÐÏÔ×Ųî±ð¡£¡£¡£¡£ ¡£¡£Õâ˵Ã÷£¬£¬£¬£¬£¬×Ïɼ´¼µÄʹÓÃÔö½øÑª¹ÜÉú³¤¡¢ÔöÌí°©Ï¸°û×ªÒÆÎ¢ÇéÐΣ¬£¬£¬£¬£¬ÕâЩӰÏì¶¼ÊÇͨ¹ýAtf3»ùÒòʵÏֵġ£¡£¡£¡£ ¡£¡£

ͼƬ

°©Ï¸°ûͨ¹ýTMEM½øÈëѪ¹Ü

Ö»¹Ø×¢Ô­·¢Ö×Áö»¹²»·ó£¬£¬£¬£¬£¬Ñо¿Ö°Ô±ÓÖ¶¢ÉÏÁ˰©Ï¸°û×ªÒÆµÄÄ¿µÄ×éÖ¯——·Î²¿¡£¡£¡£¡£ ¡£¡£ËûÃǸøÓÃ×Ïɼ´¼Ô¤´¦Öóͷ£¹ýµÄСÊó¾²Âö×¢É䰩ϸ°û£¬£¬£¬£¬£¬×îºéÁ÷ƽµØÏû³ýÁË×Ïɼ´¼¶Ô°©Ï¸°ûµÄÖ±½ÓɱÉËÓ°Ïì¡£¡£¡£¡£ ¡£¡£

Ч¹ûÏÔʾ£¬£¬£¬£¬£¬×¢Éä¹ý×Ïɼ´¼µÄʵÑé×é·Î×éÖ¯±È±ÈÕÕ×éÓиü¶àµÄ°©Ï¸°û¶¨Ö³¡£¡£¡£¡£ ¡£¡£¶Ô·Î×éÖ¯µÄ¼ì²â·¢Ã÷£¬£¬£¬£¬£¬ÊµÑé×éÖд©¿×ËØ£¨Prf1£©±í´ïϵ÷£¬£¬£¬£¬£¬Ñ×Ö¢ÐÔµ¥ºËϸ°û£¨iMs£©ÊýÄ¿ÉÏÉý£¬£¬£¬£¬£¬Ç÷»¯Òò×ÓÅäÌå2£¨CCL2£©±í´ïÉϵ÷¡£¡£¡£¡£ ¡£¡£

Prf1ÊÇÖ÷ÒªµÄÈܾúÂѰ×Ö®Ò»£¬£¬£¬£¬£¬±£´æÓÚϸ°û¶¾ÐÔTϸ°ûºÍ×ÔȻɱÉË£¨NK£©Ï¸°ûÖУ¬£¬£¬£¬£¬ÓÐÒÖ°©×÷ÓÃ[6]£»£»iMs¿ÉÒÔ½øÈë·ÎÖзֽâ³É¾ÞÊÉϸ°û£¬£¬£¬£¬£¬Ôö½øÖ×Áö×ªÒÆ[7]£»£»¶øCCL2ÊÇÒ»ÖÖС·Ö×ÓÂѰף¬£¬£¬£¬£¬¿ÉÒÔÔö½øÑ×Ö¢ÐÔµ¥ºËϸ°û¸»¼¯£¬£¬£¬£¬£¬ÔöÇ¿Ñ×Ö¢·´Ó¦£¬£¬£¬£¬£¬¶ÔÖ×ÁöÉú³¤Æð×ÅÖ÷Òª×÷ÓÃ[8]¡£¡£¡£¡£ ¡£¡£

ͬÑù£¬£¬£¬£¬£¬ÕâЩЧ¹ûÒ²Ö»·ºÆðÔÚÒ°ÉúÐÍСÊóÉÏ¡£¡£¡£¡£ ¡£¡£Õâ˵Ã÷£¬£¬£¬£¬£¬×Ïɼ´¼µÄʹÓøıäÁË·Î×éÖ¯µÄ΢ÇéÐΣ¬£¬£¬£¬£¬Ê¹°©Ï¸°û¸üÈÝÒ×ÔÚ·Î×éÖ¯É϶¨Ö³£¬£¬£¬£¬£¬ÕâЩӰÏìÒ²ÊÇͨ¹ýAtf3»ùÒòʵÏֵġ£¡£¡£¡£ ¡£¡£

ÄÇôÏÖÔÚÎÒÃÇ¿ÉÒÔÈ·¶¨ÁË£¬£¬£¬£¬£¬×Ïɼ´¼Ò»·½Ãæ´ÙʹÖ×Áöϸ°û´ÓÔ­·¢Ö×ÁöÌÓÀ룬£¬£¬£¬£¬Ò»·½Ãæ¸Ä±ä·Î²¿Î¢ÇéÐÎʹ֮¸üÊʺÏÖ×Áöϸ°û¶¨Ö³£¬£¬£¬£¬£¬¶øAtf3»ùÒòÔÚÆäÖÐÆðÒªº¦×÷Óᣡ£¡£¡£ ¡£¡£

×Ïɼ´¼£¨PTX£©¶ÔÔ­·¢Ö×ÁöºÍ×ªÒÆ×éÖ¯µÄÓ°Ïì

Òª²»ÊÇ¿´µ½ÕâЩ֤¾Ý£¬£¬£¬£¬£¬Ææµã¸âÕæÊDz»¿ÏÒâÏàÐÅ£¬£¬£¬£¬£¬×Ïɼ´¼¾¹È»ÖúèîΪŰ£¡²»¹ý£¬£¬£¬£¬£¬ÕâЩÔÚСÊóÉíÉÏ»ñµÃµÄʵÑéЧ¹û£¬£¬£¬£¬£¬ÊÇ·ñÊÊÓÃÓÚÈËÀàÄØ £¿£¿£¿£¿£¿

Ñо¿ÕßÃÇ×ÔȻҲ˼Á¿µ½ÁËÕâÒ»µã¡£¡£¡£¡£ ¡£¡£ÎªÁË֤ʵСÊóÊý¾ÝÓëÈËÀà°©Ö¢µÄÏà¹ØÐÔ£¬£¬£¬£¬£¬ËûÃÇ´Ó¹ûÕæµÄÖ×ÁöÊý¾Ý¿â[9]ÖеÄÑù±¾Êý¾Ý¾ÙÐÐÁËÆÊÎö¡£¡£¡£¡£ ¡£¡£Ð§¹û²»³öËùÁÏ£¬£¬£¬£¬£¬ÔÚ½ÓÊÜÁË»¯ÁƵÄÈéÏÙ°©»¼ÕßµÄÖ×Áö×éÖ¯ÖУ¬£¬£¬£¬£¬Atf3ÕæµÄÓиü¸ßµÄ±í´ï¡£¡£¡£¡£ ¡£¡£ÏìÓ¦µÄ£¬£¬£¬£¬£¬»¼ÕßÒ²·ºÆðÁ˸ßˮƽµÄCCL2¡¢CCL7¡¢CCL8µÈÑ×Ö¢Ö¸±êÒÔ¼°µÍˮƽµÄPrf1¡¢NKϸ°ûºÍϸ°û¶¾ÐÔTϸ°ûµÈ¡£¡£¡£¡£ ¡£¡£

ÔÚÈéÏÙ°©¡¢·Î°©¡¢Âѳ²°©ºÍ½á³¦°©ÖУ¬£¬£¬£¬£¬ATF3»ùÒòºÍTEK»ùÒò¸ß±í´ï£¨ºì£©ºÍµÍ±í´ï£¨ÂÌ£©¶Ô»¼ÕßÉúÑÄÂʵÄÓ°Ïì

ÕâЩÆÊÎöЧ¹ûÓëСÊóÊÔÑéµÄ±íÕ÷ÊÇÒ»Öµģ¬£¬£¬£¬£¬¿É¼ûСÊóÊÔÑéЧ¹û¼òÖ±ÄÜÕ¹ÏÖ×Ïɼ´¼ÔÚÈËÌå°©Ö¢×ªÒÆÖÐÆðµ½µÄ×÷Óᣡ£¡£¡£ ¡£¡£

Ñо¿Ö°Ô±»¹Ê¹ÓÃÆäËûÖêϵµÄ°©Ï¸°ûÌæ»»ÁËËûÃÇÔÚÕâ´ÎʵÑéÖÐËùÓõÄÈéÏÙ°©Ï¸°û£¬£¬£¬£¬£¬»¹ÊµÑéÓÃÆäËû»¯ÁÆÒ©ÎïÈç»·Á×õ£°·£¨CTX£©Ìæ»»×Ïɼ´¼£¬£¬£¬£¬£¬ÉõÖÁ»¹Ê¹Óòî±ðÖÖϵµÄСÊó¾ÙÐÐÁËʵÑ飬£¬£¬£¬£¬Ð§¹ûÎÞÒ»ÆÆÀý¡£¡£¡£¡£ ¡£¡£Atf3»ùÒò½éµ¼µÄ»¯ÁƼÁ¶Ô°©Ö¢·Î×ªÒÆµÄÔö½ø×÷Óò»¾ÖÏÞÓÚ¼òµ¥»¯ÁÆÒ©Îï¡¢µ¥¸ö°©ÖÖ»òµ¥¸öÊÔÑ鹤¾ß£¬£¬£¬£¬£¬ÕâÊÇÒ»ÖÖÔÚ»¯ÁÆÖÐÆÕ±é±£´æµÄÕ÷Ï󡣡£¡£¡£ ¡£¡£

¼øÓÚÔçÏÈÓÐÑо¿Åú×¢£¬£¬£¬£¬£¬È«Éí»¯Áƺó²ÐÁôµÄÖ×ÁöÓëÁÙ´²ÉϵIJ»Á¼Ô¤ºóÓйØ[10]£¬£¬£¬£¬£¬ÄÇô£¬£¬£¬£¬£¬Õâ¸öÑо¿¿ÉÒÔ˵ÊǶÔÒÔºó»¯ÁƵÄʹÓúÜÓÐÁÙ´²ÒâÒåÁË¡£¡£¡£¡£ ¡£¡£Hai½ÌÊÚÌåÏÖ£¬£¬£¬£¬£¬»òÐíδÀ´¿ÉÒÔͨ¹ýÒÖÖÆAtf3»ùÒòµÄ±í´ïÀ´É¨³ý»¯ÁƵÄÕâ¸ö¸±×÷Ó㬣¬£¬£¬£¬ÕâÒ²ÊÇËûÃǵÄÏÂÒ»¸öÑо¿Ä¿µÄ¡£¡£¡£¡£ ¡£¡£

²»¹ýÕâ¸öÑо¿Ò²±£´æÒ»Ð©¾ÖÏÞÐÔ£º¶ÔСÊóµÄÕûÌåÑо¿Ã»Óв½·¥È·¶¨ÔÚ²î±ðÀàÐÍϸ°ûÖÐAtf3»ùÒòµÄ×÷Ó㻣»²¢ÇÒ³ýÁËѪ¹Ü×ªÒÆÍ¾¾¶Ö®Í⣬£¬£¬£¬£¬°©Ï¸°ûÒ²¿ÉÒÔͨ¹ýÁܰ͹Ü×ªÒÆ£¬£¬£¬£¬£¬Atf3»ùÒò¶ÔÕâÌõõè¾¶µÄÓ°Ï컹δ¿ÉÖªµÈµÈ¡£¡£¡£¡£ ¡£¡£

“Ñо¿ÕßÓ¦µ±ËæÊ±¼á³ÖÒ»¸ö̹µ´µÄÑ۽硣¡£¡£¡£ ¡£¡£”Hai½ÌÊÚÔÚÒ»´Î²É·ÃÖÐÈçÊÇ˵[11]¡£¡£¡£¡£ ¡£¡£Ææµã¸âÏ룬£¬£¬£¬£¬¿ÆÑ§»òÐí¾ÍÊÇÔÚ¶ÔǰÈ˵ÄÇ㸲ÉÏһֱǰÐС¢Ò»Ö±Ç°½øµÄ°É¡£¡£¡£¡£ ¡£¡£

²Î¿¼×ÊÁÏ£º

[1] "Paclitaxel". The American Society of Health-System Pharmacists. Retrieved January 2, 2015.

[2] Yi Seok Chang, Swati P. Jalgaonkar, Justin D. Middleton, Tsonwin Hai.Proceedings of the National Academy of Sciences, 2017; 201700455 DOI: 10.1073/pnas.1700455114.

[3] Corradini P, Ladetto M, Pileri A, Tarella C (1999) Clinical relevance of minimal residual disease monitoring in non-Hodgkin’s lymphomas: A critical reappraisal of molecular strategies. Leukemia 13:1691–1695.

[4] Harney AS, et al. (2015) Real-time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by TIE2hi macrophage-derived VEGFA. Cancer Discov 5:932–943.

[5] George S. Karagiannis, Jessica M. Pastoriza, Yarong Wang et al. Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. Science Translational Medicine, 05 Jul 2017, 9(397):eaan0026, doi:10.1126/scitranslmed.aan0026.

[6] Barry M, Bleackley RC (2002) Cytotoxic T lymphocytes: All roads lead to death. Nat Rev Immunol 2:401–409.

[7] Qian BZ, et al. (2011) CCL2 recruits inflammatory monocytes to facilitate breasttumour metastasis. Nature 475:222–225.

[8] Qian B, et al. (2009) A distinct macrophage population mediates metastatic breast

cancer cell extravasation, establishment and growth. PLoS One 4:e6562.

[9] Boersma BJ, et al. (2008) A stromal gene signature associated with inflammatory breast cancer. Int J Cancer 122:1324–1332.

[10] Symmans WF, et al. (2017) Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol 35: 1049–1060.

[11] https://www.sciencedaily.com/releases/2017/08/170807155401.html

 

¡¾ÍøÕ¾µØÍ¼¡¿